Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

7.980 USD -0.230 (-2.80%)
Official Closing Price Updated: 4:21 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aeglea Biothera

< Previous 1 2 3 Next >
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today... 
From PR Newswire
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden... 
From PR Newswire
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
Company eligible to receive Priority Review Voucher upon FDA approval of ACN00177 
From PR Newswire
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden... 
From PR Newswire
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden... 
From PR Newswire
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177 
From PR Newswire
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden... 
From PR Newswire
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden... 
From PR Newswire
Aeglea BioTherapeutics to Participate in September Investment Conferences
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
From GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
From GlobeNewswire News Releases
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Proposed Public Offering
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
From GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
From GlobeNewswire News Releases
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020 
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
From GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
From GlobeNewswire News Releases
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference
Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9 
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 
From GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
From GlobeNewswire News Releases
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
Designation Follows Recently Reported ARG1-D Phase 1/2 Data Demonstrating Clinical Response in Patients Treated with Pegzilarginase 
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.